Six-minute walk test could help guide heart failure treatment

April 15, 2014
Six-minute walk test could help guide heart failure treatment

(HealthDay)—Distance achieved in the six-minute walk test may be a practical measure of functional capacity that guides selection of therapy for patients with heart failure, according to research published online April 9 in the Journal of the American College of Cardiology.

Daniel P. Fishbein, M.D., of Duke University in Durham, N.C., and colleagues conducted a six-minute walk test in 2,397 patients with prior to random assignment in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). The researchers assessed the association between the distance on the six-minute walk test and mortality according to treatment selection.

The researchers found that risk of mortality for with an implantable cardioverter defibrillator (ICD) versus placebo according to hazard ratio [HR] for tertiles of distance on the six-minute walk test was 0.42 (95 percent confidence interval [CI], 0.26 to 0.66) for the top tertile, greater than 386 m; 0.57 (95 percent CI, 0.39 to 0.83) for the middle tertile, 288 to 386 m; and 1.02 (95 percent CI, 0.75 to 1.39) for the bottom tertile, less than 288 m. The corresponding HRs for amiodarone therapy versus placebo were 0.68 (95 percent CI, 0.46 to 1.02) for the top tertile, 0.86 (95 percent CI, 0.61 to 1.21) for the middle tertile, and 1.56 (95 percent CI, 1.17 to 2.09) for the bottom tertile of distance on the six-minute walk test. In a secondary analysis of cause-specific mortality, ICD therapy reduced arrhythmic mortality in the top two tertiles of the six-minute walk test but had no effect on heart failure mortality.

"In summary, patients with a six-minute walk distance of less than 288 meters did not derive benefit from either prophylactic implantation or amiodarone therapy," the authors write.

Several pharmaceutical companies contributed funding to the SCD-HeFT trial.

More information: Full Text (subscription or payment may be required)

Related Stories

Clopidogrel after MI less effective in diabetes patients

September 5, 2012

(HealthDay)—Clopidogrel therapy following a heart attack does less to reduce the risk of death in patients with diabetes than in those without diabetes, according to a study published in the Sept. 5 issue of the Journal ...

Improved outcomes seen with ventricular assist devices

January 31, 2014

(HealthDay)—Among Medicare patients receiving implantation of ventricular assist devices (VADs) for advanced heart failure, mortality has decreased, but readmission rates did not change, according to research published ...

Melanoma risk up in IBD independent of biologic therapy

January 31, 2014

(HealthDay)—Inflammatory bowel disease (IBD) is associated with an increased risk of melanoma, independent of the use of biologic therapy, according to research published in the February issue of Clinical Gastroenterology ...

Nocturnal respiratory rate predicts cardiac risk after MI

March 10, 2014

(HealthDay)—Among survivors of acute myocardial infarction (MI), nocturnal respiratory rate (NRR) is significantly associated with cardiac mortality, particularly non-sudden cardiac death, according to research published ...

Interarm BP difference may up cardiac risk in diabetes

April 3, 2014

(HealthDay)—Interarm differences in systolic blood pressure (BP) in patients with diabetes may be associated with an increased risk of cardiovascular morbidity and mortality, according to research published online on March ...

Recommended for you

Heart attack treatment hypothesis 'busted'

July 6, 2015

Researchers have long had reason to hope that blocking the flow of calcium into the mitochondria of heart and brain cells could be one way to prevent damage caused by heart attacks and strokes. But in a study of mice engineered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.